Bolt Biotherapeutics, Inc. financial data

Symbol
BOLT on Nasdaq
Location
Redwood City, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 324% % -29%
Debt-to-equity 86% % 101%
Return On Equity -98% % -40%
Return On Assets -52% % -7.8%
Operating Margin -884% % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,919,441 shares -95%
Common Stock, Shares, Outstanding 1,919,441 shares -95%
Entity Public Float $21,900,000 USD -32%
Common Stock, Value, Issued $0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 1,919,441 shares 0.36%
Weighted Average Number of Shares Outstanding, Diluted 1,919,441 shares 0.36%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $5,195,000 USD -47%
Research and Development Expense $35,267,000 USD -43%
General and Administrative Expense $14,625,000 USD -27%
Operating Income (Loss) $45,944,000 USD 39%
Nonoperating Income (Expense) $3,263,000 USD -70%
Net Income (Loss) Attributable to Parent $42,681,000 USD 34%
Earnings Per Share, Basic 9 USD/shares 53%
Earnings Per Share, Diluted 9 USD/shares 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $17,753,000 USD 90%
Cash, Cash Equivalents, and Short-term Investments $38,800,000 USD -54%
Assets, Current $35,606,000 USD -38%
Property, Plant and Equipment, Net $1,500,000 USD -58%
Operating Lease, Right-of-Use Asset $19,881,000 USD 19%
Other Assets, Noncurrent $179,000 USD -38%
Assets $65,053,000 USD -41%
Accounts Payable, Current $1,518,000 USD 2.4%
Employee-related Liabilities, Current $1,932,000 USD -41%
Liabilities, Current $9,966,000 USD -45%
Operating Lease, Liability, Noncurrent $20,889,000 USD 36%
Other Liabilities, Noncurrent $133,000 USD
Liabilities $32,952,000 USD -12%
Accumulated Other Comprehensive Income (Loss), Net of Tax $10,000 USD -105%
Retained Earnings (Accumulated Deficit) $454,148,000 USD -10%
Stockholders' Equity Attributable to Parent $32,101,000 USD -55%
Liabilities and Equity $65,053,000 USD -41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,365,000 USD 20%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $14,551,000 USD 43%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,919,441 shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,186,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19,518,000 USD 75%
Deferred Tax Assets, Valuation Allowance $96,870,000 USD 16%
Deferred Tax Assets, Gross $103,379,000 USD 15%
Operating Lease, Liability $23,589,000 USD 30%
Depreciation $100,000 USD -97%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $42,896,000 USD 34%
Lessee, Operating Lease, Liability, to be Paid $32,844,000 USD 27%
Property, Plant and Equipment, Gross $8,632,000 USD -17%
Operating Lease, Liability, Current $2,700,000 USD -4.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,584,000 USD 60%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,399,000 USD 24%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 8.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9,255,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,775,000 USD 60%
Deferred Tax Assets, Operating Loss Carryforwards $53,485,000 USD 13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $23,832,000 USD 27%
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,974,000 USD 60%
Operating Lease, Payments $1,242,000 USD 3.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $399,000 USD -13%
Deferred Tax Assets, Net of Valuation Allowance $6,509,000 USD 8.8%
Share-based Payment Arrangement, Expense $2,923,000 USD -65%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%